Santen Pharmaceutical Co. Ltd

Research Santen Pharmaceutical Co. Ltd (SZD) on Bullrun: valuation model: 10.0% undervalued, market cap EUR 3.67B, P/E 18.4, dividend yield 2.0%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSZD
• ExchangeF
• CountryJapan
• SectorHealthcare
• IndustryDrug Manufacturers - General
• CurrencyEUR
• Valuation signal10.0% undervalued
• Market capEUR 3.67B
• P/E18.4
• Dividend yield2.0%
• Financial periodFY2025
• RevenueEUR 300.00B
• Revenue growth-0.6%
• Net incomeEUR 36.26B
• Gross margin57.0%

Valuation Snapshot

Bullrun's latest valuation model marks Santen Pharmaceutical Co. Ltd as 10.0% undervalued; latest market cap is EUR 3.67B; P/E is 18.4; dividend yield is 2.0%.

About Santen Pharmaceutical Co. Ltd

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension;

Frequently asked questions

Is Santen Pharmaceutical Co. Ltd overvalued or undervalued?

Bullrun's valuation model currently marks Santen Pharmaceutical Co. Ltd as 10.0% undervalued.

What is Santen Pharmaceutical Co. Ltd's market cap?

Santen Pharmaceutical Co. Ltd's market capitalization is EUR 3.67B.

What is Santen Pharmaceutical Co. Ltd's P/E ratio?

Santen Pharmaceutical Co. Ltd's price-to-earnings (P/E) ratio is 18.4.

Does Santen Pharmaceutical Co. Ltd pay a dividend?

Santen Pharmaceutical Co. Ltd has a dividend yield of 2.0%.

What does Santen Pharmaceutical Co. Ltd do?

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally.